passagebio.comHealthcareFounded: 2018Funding to Date: $225.5MM
Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).
View Enterprise Value for Passage Bio.